AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
192.68
-1.15 (-0.59%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close193.83
Open193.48
Bid189.98 x 1200
Ask194.18 x 900
Day's Range192.34 - 193.76
52 Week Range114.27 - 194.61
Volume2,085,813
Avg. Volume2,252,850
Market Cap63.252B
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.96 (1.53%)
Ex-Dividend DateNov 10, 2019
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    SkinMedica® Launches New Instant Bright Eye Cream For Immediate, Visible Results

    Allergan plc (NYSE: AGN) announced today the launch of the SkinMedica® Instant Bright Eye Cream, a refreshing eye treatment that hydrates, brightens and helps visibly firm the appearance of the delicate skin around the eyes. The product is designed to immediately improve the appearance of the eyes and continues reducing the visible signs of aging and fatigue over time—including dark circles, fine lines and crepiness of upper eyelids. For its most comprehensive regimen, SkinMedica® is also introducing Instant Bright Eye Mask, a set of hydrogel eye patches that reduce the appearance of puffiness and provide a hydrating boost for under the eyes.

  • Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma's Impact on Daily Living
    PR Newswire

    Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma's Impact on Daily Living

    Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, announced today a partnership with Von Miller, Super Bowl MVP, Denver Broncos linebacker and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the 'My Glaucoma' campaign, Miller will address the misunderstandings and impact of glaucoma and encourage those with the disease, and their caregivers, to take early action. This includes going regularly to the doctor and taking medications as prescribed. Additional information can be found at www.MyGlaucoma.com.

  • Business Wire

    Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation

    Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Sandoz Inc. (Sandoz) resolving patent litigation brought in response to Sandoz’s abbreviated new drug application (ANDA) seeking approval to market generic versions of LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents. The settlement with Sandoz is the fourth patent infringement settlement the companies have reached with respect to LINZESS.

  • PR Newswire

    Warner Chilcott and Watson Resolve Antitrust Class Action Litigation with Direct and Indirect Purchasers of Loestrin 24 Fe and Minastrin 24 Fe

    Allergan plc (NYSE: AGN), today announced that its Warner Chilcott and Watson subsidiaries have reached resolutions with all plaintiffs, including a class of direct purchasers, individual direct purchasers that previously opted out of the direct purchaser class, and a class of indirect purchasers of Loestrin 24 Fe and Minastrin 24 Fe, concluding the previously disclosed antitrust litigation in the U.S. District Court for the District of Rhode Island. The settlements make no admission of wrongdoing on the part of the company and resolve the litigation that was scheduled to go to trial on January 6, 2020.

  • PR Newswire

    Allergan Receives U.S. FDA Approval for UBRELVY™ for the Acute Treatment of Migraine with or without Aura in Adults

    Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for UBRELVY™ (ubrogepant) for the acute treatment of migraine with or without aura in adults. UBRELVY™ is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start. Migraine is a neurological disease characterized by intermittent migraine attacks with symptoms that are often incapacitating. Migraine afflicts 31 million Americans and is the third most common disease and second leading cause of disability worldwide.

  • PR Newswire

    Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration

    Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA.

  • Allergan Foundation Giving Reaches $95 Million Since Inception
    PR Newswire

    Allergan Foundation Giving Reaches $95 Million Since Inception

    Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that The Allergan Foundation has awarded a total of $10 million in charitable grants in 2019. The grants were donated to more than 400 organizations in 32 states as part of The Allergan Foundation's commitment to providing a lasting and positive impact in the communities in which Allergan employees live and work. The 2019 grants bring The Allergan Foundation's total donations in its 21-year history to approximately $95 million, including $45 million since 2015.

  • PR Newswire

    BOTOX® (onabotulinumtoxinA) Celebrates 30 Years of Endless Innovation

    Allergan plc (NYSE: AGN) is commemorating today the beginning of the 30th anniversary celebration for BOTOX® this year with the ringing of the New York Stock Exchange opening bell. Over the past 30 years, more than 100 million vials of BOTOX® and BOTOX® Cosmetic have been manufactured worldwide, providing a trusted and effective treatment option for various therapeutic and aesthetic uses. With two additional U.S. Food and Drug Administration (FDA) approvals this year for therapeutic indications of pediatric upper limb spasticity and pediatric lower limb spasticity, excluding spasticity caused by cerebral palsy, BOTOX® and BOTOX® Cosmetic now proudly hold 14 therapeutic and aesthetic indications combined, reinforcing its leadership in neurotoxin science.

  • PR Newswire

    Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine

    Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the December 5th issue of The New England Journal of Medicine (NEJM). The data from this second published pivotal trial reinforced that the acute treatment of migraine with ubrogepant, compared with placebo, led to significantly greater rates of pain freedom and freedom from the most bothersome migraine-associated symptom at two hours with both the 50 mg and 100 mg doses. If FDA-approved, ubrogepant would be the first available and approved small molecule, oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine.

  • Business Wire

    National Consumer Rights Law Firm FeganScott Files Second, Expanded Class-Action Lawsuit Against Allergan

    Allergan, the manufacturers of BIOCELL textured “gummy” breast implants, is the target of a second proposed national class-action lawsuit by consumer-rights law firm FeganScott. The expanded complaint, which broadens the range of the allegedly defective products covered by the suit, claims that although the FDA issued a recall for Allergan’s BIOCELL products, the company has no plans to provide medical monitoring for individuals at risk of developing breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).

  • PR Newswire

    Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association

    DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Allergan plc (AGN) today announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the November 19th issue of The Journal of the American Medical Association (JAMA). If approved, ubrogepant would potentially be the first FDA-approved small molecule, oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine.

  • Allergan® Announces First Annual National BOTOX® Cosmetic (onabotulinumtoxinA) Day
    PR Newswire

    Allergan® Announces First Annual National BOTOX® Cosmetic (onabotulinumtoxinA) Day

    DUBLIN, Nov. 18, 2019 /PRNewswire/ -- Allergan plc (AGN), the maker of BOTOX® Cosmetic, has announced the first-ever National BOTOX® Cosmetic Day kicking off on November 20. Just in time for the holiday season, National BOTOX® Cosmetic Day is a moment to engage loyal consumers and healthcare providers, as well as those considering treatment, in a conversation about owning their look, with fewer lines, with BOTOX® Cosmetic. BOTOX® Cosmetic is the only treatment of its kind that is FDA approved for temporary improvements in moderate to severe crow's feet, frown lines, and forehead lines in adults.